Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics.
By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
B2B
26 to 50
Series A
$16 M
Scaling Up
2015
Medical Devices
Biotechnology
Improve Discovery/Safety & Efficacy
Increase Efficiency
Analytics
Service
Yes
Active
Machine Learning
N/A
Software
Principal Electrical Engineer
Seattle, WA
Cardiac Stem Cell Scientist (PhD Level)
Seattle, WA
AI/ML Professionals
Want to work at Curi Bio?
We can introduce you to the right person at Curi Bio
3
1
$10M
Company was founded 2015 and it took almost 7 years (Jan 2022) to raise first external round
Investors
Interested in researching Curi Bio?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Curi Bio
Potential Customers
Interested in what they do or partnership?
Learn more about how they work